Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy DayGlobeNewsWire • 09/21/23
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023GlobeNewsWire • 09/07/23
These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?The Motley Fool • 08/24/23
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/23
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7GlobeNewsWire • 07/12/23
Axsome (AXSM) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 07/11/23
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in AdultsGlobeNewsWire • 07/07/23
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common StockGlobeNewsWire • 06/30/23
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common StockGlobeNewsWire • 06/28/23